𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Plasma concentrations and pharmacokinetics of dihydralazine after single oral doses to human subjects

✍ Scribed by A. R. Waller; L. F. Chasseaud; T. Taylor; A. Darragh; D. A. O'Kelly


Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
295 KB
Volume
1
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

After single oral doses of 20 mg of a suspension of dihydralazine sulphate to human subjects, the peak of mean plasma concentrations of dihydralazine of 47Β·0 ng ml^βˆ’1^ Β± 11Β·0 standard deviation (S.D.) (n = 7) was reached at 1 h. Mean concentrations declined biphasically with apparent half‐lives of 0Β·57 and 4Β·96 h respectively.

Dihydralazine was partly converted to hydralazine. The peak of mean plasma concentrations of the latter drug of 3Β·9 ng ml^βˆ’1^ Β± 1Β·7 S.D. (n = 7) occurred at 1–2 h after dosing with dihydralazine sulphate and declined to 1–5 ng ml^βˆ’1^ Β± 1Β·5 S.D. at 6 h.

Of the seven subjects studied, three were classified as fast and four as slow acetylators. Mean clearances appeared to be slightly more rapid in fast acetylators (1Β·63 1 min^βˆ’1^ Β± 0Β·32 S.D.) when compared to slow acetylators (1Β·31 1 min^βˆ’1^ Β± 0Β·31 S.D.) but this difference and differences in plasma concentrations and in areas under the plasma drug concentration‐time curves were not significant (p > 0Β·1).


πŸ“œ SIMILAR VOLUMES


Pharmacokinetics of fluvoxamine maleate
✍ M. H. De Vries; J. Van Harten; P. Van Bemmel; M. Raghoebar πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 286 KB πŸ‘ 2 views

The pharmacokinetics of fluvoxamine after single oral administration of 25, 50, and 100mg fluvoxamine maleate was studied in a three-way cross-over study in 12 healthy male subjects. Fluvoxamine was administered orally in a solution. For doseproportionality, AUC, and C,-dose relationships were evalu

Pharmacokinetics of furosemide after thr
✍ Elaine S. Waller; Joseph W. Massarella; Motria Sharanevych Tomkiw; Robert V. Smi πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 396 KB πŸ‘ 2 views

Furosemide solution was orally administered to 21 healthy adult males to determine dose proportionality over the dose range used and the reproducibility of disposition following a repeated dose. Furosemide solution was given in doses of 20,40, and 80mg, with the 40 mg dose repeated once. Blood was c

Pharmacokinetics of deramciclane in dogs
✍ Harri Kanerva; Hannele Huuskonen; Anneli Alhonen-Raatesalmi; Timo Nevalainen; Ar πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 204 KB πŸ‘ 2 views

The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der

Human dolasetron pharmacokinetics: II Ab
✍ Harold Boxenbaum; Todd Gillespie; Kathleen Heck; William Hahne πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 485 KB πŸ‘ 1 views

## Abstract Dolasetron is a 5‐hydroxytryptamine antagonist active at type III receptors; it is presently undergoing clinical evaluation for the reduction/prevention of cancer chemotherapyinduced nausea and vomiting. A previous study demonstrated that following intravenous administration to healthy

Single oral dose pharmacokinetics and co
✍ W. D. Hooper; M. J. Eadie; R. G. Dickinson πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 335 KB πŸ‘ 2 views

## Abstract A comparative bioavailability study was conducted with two capsule formulations of danazol (200 mg) in 16 healthy adult male volunteers. Fasting subjects received single doses (400 mg) of each formulation on separate occasions 1 week apart. Blood samples were drawn at specified times up

Clinical pharmacokinetics of procaterol:
✍ Dr Michael A. Eldon; Debbie S. Blake; Michael J. Coon; Gerald D. Nordblom; Allen πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 328 KB πŸ‘ 2 views

Procaterol is a potent, orally active &-agonist bronchodilator useful in the treatment of reversible bronchospastic disease. It is effective when administered as single or multiple (Q8H) 50 and 75pg doses. As part of the clinical development of procaterol, the pharmacokinetics and dose proportionali